 | |
| Clinical data | |
|---|---|
| Trade names | Conjupri, others |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 93% |
| Metabolism | Liver |
| Excretion | 60% of the metabolites excreted in the urine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H25ClN2O5 |
| Molar mass | 408.88 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Levamlodipine (INN), also known aslevoamlodipine orS-amlodipine is a pharmacologically activeenantiomer ofamlodipine.[1] Amlodipine belongs to thedihydropyridine group ofcalcium channel blocker used as anantihypertensive andantianginal agent.[2] It was approved by the U.S.FDA in December 2019 and is currently marketed under the brand nameConjupri.[3]
Amlodipine blocks the transmembrane influx of calcium into the vascular and cardiac smooth muscles resulting in vasodilation and hence a fall in blood pressure. Levamlodipine is an allosteric modulator and acts on the L-type ofcalcium channels.[4][5] Receptor binding studies have shown that out of the two forms only the (S)-enantiomer of amlodipine binds to and blocks L-type calcium channels whereas the (R)-enantiomer has no activity on these channels.[6]
The precise mechanisms by which levamlodipine relievesangina have not been fully explored, but are thought to include the following:
Administration of levamlodipine (2.5 mg) as a single dose gives maximum plasma concentration (Cmax) of 8.3 to 9.3 ng/mL in 2 to 3 hrs (Tmax). It is extensively (about 90%) converted to inactive metabolites via hepaticmetabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Levamlodipine shows approximately 93%plasma protein binding in hypertensive patients. The meanAUC0–t value (t = 48 hrs) of levamlodipine tablets (2.5 mg) is95±14 ng·hr/mL. The plasmaelimination half-life of levamlodipine has been found to be31±13 hrs.[7]
Various clinical studies have shown that levamlodipine has more selectivity and better efficacy than (R)-amlodipine. In pooled data, from three comparative studies conducted in 200 patients with mild to moderatehypertension, 2.5 mg of levamlodipine was found to be equivalent in its blood pressure lowering efficacy to 5 mg of amlodipine. The average reduction in systolic BP was 19±3 vs 19±4, 20±2 vs 19±3 and 20±2 vs 19±3 mm of Hg recorded in standing, supine and sitting position respectively for levamlodipine compared to racemic amlodipine. The studies also reported a significant reduction in totalcholesterol andtriglyceride levels with levamlodipine, which was not seen with amlodipine.[8][9][10]
Efficacy and safety of levamlodipine (2.5 mg, once daily) has been evaluated in the patients withisolated systolic hypertension (ISH). Levamlodipine effectively reduced the systolic BP (mean reduction 22±14 mm of Hg) in all grades of ISH. After 28 days of the treatment, overall responder rate was 73%. It significantly reduced the systolic and diastolic BP within 4 weeks with a responder rate of 96.5%.[11]
Elderly hypertensives withdiabetes mellitus exhibits higher response to levamlodipine therapy than non-diabetic patients. Levamlodipine is an effective switch-over option for the elderly patients who experienceoedema and other adverse events with racemic amlodipine.[12]
The use ofracemic amlodipine is commonly associated with adverse events likeperipheral edema and other side effects like headache, dizziness, flushing and abdominal pain.[13] Controlled clinical trials showed that levamlodipine is rarely associated with these side effects.[14] No controlled clinical study of levamlodipine has been performed in patients with hepatic impairment and renal impairment. Clinical studies in patients with normal liver function have shown that there is no elevation in the hepatic enzymes with the use of levamlodipine.[2] However, caution should be taken while administering levamlodipine to such patients.
In apostmarketing surveillance study, levamlodipine (2.5/5 mg) was found to be well tolerated (n = 1859) in patients with hypertension. Out of 314 patients, who reported peripheral edema with conventional amlodipine were switched over to levamlodipine and edema was resolved in 310 patients (98.72%) at the end of 4 weeks. Only in 4 patients was edema sustained. Only 30 patients (out of 1859) reported side effects. These side effects includedvertigo,tachycardia, cough, headache, fever, mild difficulty in breathing andedema. Adverse events were mild in nature and no serious adverse events were reported.[14]
Aside from the U.S., levamlodipine is currently marketed in Brazil under the brand nameNovanlo (Biolab Sanus) and in India asEslo (Zuventus Healthcare Ltd.),Asomex (Emcure Pharmaceutical Ltd.) andEspin (Intas Pharmaceuticals Ltd.).[15][16]
